IKT

Inhibikase Therapeutics, Inc. is an Atlanta-based clinical-stage biopharmaceutical company focused on developing innovative therapies for Parkinson's disease and related neurodegenerative disorders. Utilizing a unique dual-targeting strategy, the company aims to address both central and peripheral neurodegeneration mechanisms, targeting critical unmet needs within the Parkinson's disease patient community. With a promising pipeline of clinical candidates, Inhibikase is strategically positioned to make significant contributions to the treatment landscape, ultimately enhancing the quality of life for individuals affected by these debilitating conditions.